Rubella is the contagious viral infection of the respiratory system. Rubella is also known as German measles. Rubella is not similar to measles, although they have similar characteristics such as red rushes, but they are caused by a different virus. Rubella virus causes joint pain, low-grade fever, sore throat and skin rash. About 25% to 50% of people infected with rubella virus do not experience any symptoms.
Rubella virus spreads through the air or by close contact. It is usually spread when the person directly comes in contact with an infected person’s respiratory secretion such as mucus. Rubella can cause serious problems including the arthritis and bleeding problems. Rubella infection very serious during pregnancy, it can cause a variety of birth defects & miscarriage.
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/23029
The global rubella treatment market is segmented on basis of drug type, route of administration and distribution channel.
Drug Type
- Nonsteroidal Anti-Inflammatory Drugs
- Analgesic
Route Of Administration
- Oral
- Topical
End User
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Retail Pharmacies
Nonsteroidal anti-inflammatory drugs and analgesic drugs are used for rubella treatment or reduce symptoms. These drugs provide ease of pain, reduce itching and control fever due to rubella infection.
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/23029
Rubella infection is dangerous during pregnancy if a woman contract rubella up to 13 week of pregnancy there is a very high risk that baby can be affected with measles. Baby can develop problems such as sight or hearing loss.
Regionally, the global rubella treatment market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific Excluding China, China, and Middle East & Africa. North America is expected to lead the global market due to increasing drug manufacturing facilities and high awareness regarding infectious diseases.
Europe also shows second highest growth in the rubella treatment market due to strong laws and government guidelines regarding child and mother health. Moreover, the rubella treatment market in the Asia-Pacific region is expected to witness a significant growth rate during the forecast period due to increasing government initiatives to reduce disease complication in children.
More than 60% of the 21.5 million children who did not receive one dose vaccination in 2013 come from 6 counties India, Nigeria, Pakistan, Ethiopia, Indonesia, DR Congo.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/23029
Some of the players operating in the global rubella treatment market are Bayer AG, Novartis AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline PLC., Reckitt Benckiser Group plc, Endo International plc, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Merck & Company, Inc., Perrigo Company plc, Abbott Laboratories, Geri-Care Pharmaceuticals Corp., Kopran Ltd. and others.
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007, United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com